ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines
Initial $80m Series B From October Increased To $200m
Executive Summary
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.